Theodore Pincus to Drug Therapy, Combination
This is a "connection" page, showing publications Theodore Pincus has written about Drug Therapy, Combination.
Connection Strength
0.626
-
Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S1-3.
Score: 0.112
-
Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
Score: 0.107
-
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S20-8.
Score: 0.107
-
Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
Score: 0.107
-
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb; 34(2):250-2.
Score: 0.071
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
Score: 0.070
-
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol. 2002 Dec; 29(12):2521-4.
Score: 0.053